Business Context and Reporting Period
This Form 8-K is a current report filed by Sunshine Heart, Inc. (not Nuwellis, Inc.) on March 13, 2013. The filing reports corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director, as well as the scheduling of the 2013 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on corporate governance and administrative events.
Material Changes
- Board Expansion: The Board of Directors increased its size from seven (7) to eight (8) members effective March 13, 2013.
- New Director Appointment: Mr. Jon Salveson was elected to fill the new vacancy in Class II of the Board. He will serve until his successor is appointed or until the 2015 annual meeting.
- Director Background: Mr. Salveson is the Vice Chairman of Investment Banking at Piper Jaffray with extensive experience in the medical device industry.
Guidance, Outlook, and Corporate Events
- Annual Meeting: The 2013 Annual Meeting of Stockholders is scheduled for May 23, 2013.
- Record Date: The record date for stockholders entitled to vote is April 20, 2013.
- Proposal Deadlines: Due to the timing of the annual meeting, the deadline for stockholder proposals (Rule 14a-8) and director nominations to be presented at the meeting is March 24, 2013.
- Compensation: Non-employee directors receive a base annual retainer of $55,000 (Chairman: $105,000) and are eligible for stock options. Mr. Salveson entered into a standard indemnity agreement.
Key Facts for Investor Verification
- Verify the company name is Sunshine Heart, Inc., as the input metadata referenced Nuwellis, Inc.
- Confirm the new board composition and Mr. Salveson's specific qualifications in the medical device sector.
- Note the strict deadline of March 24, 2013, for submitting stockholder proposals or director nominations for the upcoming May 2013 meeting.
- Review the definitive proxy statement (Schedule 14A) for full details on the director compensation program referenced in this filing.